This quarter's results are backward-looking and immaterial for a pre-revenue biotech awaiting two PDUFA catalysts. The stock will trade on the binary outcomes of FDA approvals for bezuclastinib in GIST (Nov 30) and NonAdvSM (Dec 30), not on a $0.04 EPS miss on an expected negative number. Monitor street-side analyst updates on launch revenue estimates and any FDA advisory committee briefing documents ahead of the PDUFA dates.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 10 $41.53entry
- T+1 · 3mo ago −6.81%α −6.49% · $38.70
- T+5 · 3mo ago −8.81%α −8.77% · $37.87
- T+20 · 2mo ago −15.05%α −14.13% · $35.28
- T+60 · 14d ago −25.21%α −22.79% · $31.06
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cogent Biosciences reported Q2 2026 net loss of $96.4 million (EPS $-0.60 vs consensus $-0.56, a 6.2% miss) as R&D and G&A expenses scaled for commercial readiness ahead of dual PDUFA dates for bezuclastinib in GIST (Nov 30) and NonAdvSM (Dec 30). Cash position of $792.3 million plus $73.6 million in post-quarter ATM proceeds provides runway into late 2028, but the quarter's results are secondary to the binary regulatory catalysts.
Key Financial Metrics
Key Facts
- Net loss widened to $96.4M in Q2 2026 from $73.5M in Q2 2025, driven by increased R&D ($70.8M vs $62.2M) and G&A ($31.8M vs $13.4M) as the company builds commercial infrastructure
- Cash, equivalents and marketable securities stood at $792.3M as of June 30, 2026; pro forma cash of $865.9M including $73.6M in ATM proceeds
- EPS of $-0.60 missed consensus estimate of $-0.56 by 6.2%, a modest miss for a pre-revenue biotech where EPS is driven by expense timing, not business deterioration
- NDA for bezuclastinib in GIST accepted with priority review, PDUFA date of November 30, 2026
- NDA for bezuclastinib in NonAdvSM submitted, PDUFA date of December 30, 2026; NDA for AdvSM submitted June 30, 2026
- Inducement grants of 226,700 options and 189,700 RSUs made to 59 new commercial employees on August 4 and August 10, 2026
Financial Impact
Net loss $96.4M; operating expenses $102.6M; no revenue; cash burn rate approximately $100M/quarter
Risk Factors
- FDA could issue Complete Response Letter for bezuclastinib in GIST or NonAdvSM, delaying or denying approval
- Commercial execution risk: if approved, investor expectations around launch trajectory may be high given the $7.2B market cap
- Cash burn may accelerate with commercial buildout; post-quarter ATM filing suggests potential need for additional capital beyond late 2028
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341783 |
Track record
13 reports on COGT
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +17.43% at T+20 after the Jun 12, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $31.65 Now $27.44 −13.29% settles Feb 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 5/10 Viewing Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Jun 12, 202622w ago Press Release Neutral 4/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- Jun 12, 202622w ago Press Release Bullish 7/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- May 30, 202624w ago Press Release Bullish 8/10 Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
- May 28, 202624w ago Press Release Bullish 8/10 Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers